.jpg)
You’ve probably seen the name John Baker popping up if you follow the high-stakes world of biotech acquisitions. For a long time, he was a fixture at Abcam, the Cambridge-based life sciences giant that basically dominates the world of research antibodies. But if you’re looking for a current bio of him as the Chief Commercial Officer (CCO), you’re going to run into a bit of a timeline snag.
Here is the thing: the biotech world moves fast, and the corporate rosters move even faster.
John Baker didn't just hold one title at Abcam. Over nearly a decade, he was a Swiss Army knife for the executive team. He wasn't just "the sales guy." He was the Senior Vice President of Supply Chain and Manufacturing, the head of Portfolio and Business Development, and the leader of Product Portfolio & Innovation. Basically, if it involved getting a product from a lab bench to a scientist’s freezer, he probably had a hand in it.
🔗 Read more: Integrated DNA Technologies Stock: Why You Can’t Actually Buy It (And What to Do Instead)
The Abcam Era and the $5.7 Billion Exit
When people search for John Baker chief commercial officer Abcam, they’re usually looking for the architect of the growth that led to the company's massive payday. Abcam was the "Amazon of antibodies." It was a powerhouse.
Baker joined in 2015, coming off a six-year stint as a leader in Bain & Company's Global Healthcare Practice. That’s a heavy-duty background. You don’t spend six years at Bain unless you know how to dissect a balance sheet and a supply chain with surgical precision.
At Abcam, he helped steer the ship through a period of "exceptional growth," as the industry likes to call it. This wasn't just organic growth; it was a series of aggressive moves and partnerships. He was there for the big stuff:
- Integrating acquisitions like Expedeon to bolster their proteomics and conjugation toolkit.
- Forging alliances with heavy hitters like Cancer Research UK and Molecular Devices.
- Navigating the logistical nightmare of global supply chains during the early 2020s.
Then came 2023. The big one. Danaher Corporation—a behemoth in the life sciences space—bought Abcam for approximately $5.7 billion. For the executive team, including Baker, this was the ultimate "mission accomplished" moment.
Where is John Baker Now?
If you're looking for him at Abcam today, you won't find him. After the Danaher transition settled in, Baker did what many top-tier biotech execs do after a multi-billion dollar exit: he leveled up.
👉 See also: Why the McDonald's broken ice cream machine is a total mess—and why it's finally getting fixed
In September 2024, John Baker was named the Chief Executive Officer (CEO) of IMU Biosciences.
It’s a different kind of challenge. IMU Biosciences is a London-based biotech company that uses AI to map the human immune system. We're talking systems-level immune profiling. Instead of just selling the tools (like antibodies), he's now leading a company that’s trying to use deep data to drive precision medicine. It’s a move from the "tools" side of the industry to the "intelligence" side.
Honestly, it makes sense. If you’ve spent a decade understanding the molecular tools scientists need, the next logical step is figuring out how to use AI to make sense of the data those tools produce.
The Background: More Than Just a Suit
One thing that gets lost in the corporate titles is that Baker actually knows the science. He’s not just a guy with an MBA. He trained as a veterinarian at the University of Cambridge.
Think about that for a second. Most C-suite executives come from finance or straight business backgrounds. Baker has a DPhil in Clinical Medicine from Oxford. He’s published research on the molecular biology of the innate immune response. When he’s talking about immune profiling at IMU or antibody validation at Abcam, he actually understands what’s happening at the cellular level.
That "scientist-first" perspective is likely why he was able to jump from supply chain to marketing to portfolio development so seamlessly.
Why This Matters for the Industry
The career trajectory of someone like John Baker tells us a lot about where biotech is heading in 2026.
First, the "tools" market is consolidating. With Danaher swallowing Abcam, the giants are getting bigger. Second, the leadership talent is migrating toward AI and Precision Medicine. Baker’s move to IMU Biosciences is a signal. The money and the talent are chasing the ability to decode the immune system, not just observe it.
He also sits on boards for companies like SomaServe and has historical ties to BrickBio. He’s deeply embedded in the "Golden Triangle" (London, Oxford, Cambridge) ecosystem.
Actionable Insights for Biotech Professionals
If you are following Baker’s career or looking to replicate that kind of trajectory in the life sciences sector, here are a few takeaways that aren't just corporate fluff:
- Diversify Your Functional Roles: Baker didn't stay in one silo. He moved between Supply Chain, R&D, and Business Development. In modern biotech, being a "specialized generalist" is the most valuable thing you can be.
- The Academic-to-Commercial Bridge: If you have a PhD or a clinical background, don't just stay in the lab. The industry is starving for leaders who can speak "science" to the researchers and "ROI" to the investors.
- Follow the Data: The shift from Abcam (physical products) to IMU Biosciences (AI-driven data) is the blueprint for the next decade. If you aren't getting literate in how AI is being applied to biology, you're falling behind.
- Networking in Hubs: Baker’s career is a masterclass in leveraging the UK biotech scene. Whether you are in Cambridge, UK, or Cambridge, MA, being physically and professionally present in these clusters is still the fastest way to the C-suite.
John Baker might not be the CCO of Abcam anymore, but his fingerprints are all over the company's $5.7 billion legacy. Now, he's just trying to do it all over again in the world of AI-driven immunology. Keep an eye on IMU Biosciences; if history is any indication, they’re likely being groomed for something big.